Celldex Therapeutics Inc (CLDX)
Celldex Therapeutics, Inc. is a biopharmaceutical company focused on developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and related diseases. Its pipeline includes monoclonal and bispecific antibody candidates designed to address mast cell mediated conditions where existing treatments are considered inadequate. Key clinical programs include Barzolvolimab (CDX-0159), a monoclonal antibody that binds the KIT receptor and inhibits its activity for potential use in chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis, as well as CDX-622, a bispecific candidate for inflammatory diseases that targets thymic stromal lymphopoietin and mast cell survival pathways. The company is headquartered in Hampton, New Jersey, and its common stock trades on NASDAQ under the symbol CLDX.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-CLDX
|
$22.50
|
-23.1% Downside
|
Overvalued
|
$63.07
|
115.6% Upside
|
Bargain
|
Weak
|
0.0%
|
November 11, 2026
|
3.2x
|
14,537.9x
|
2.297 B
|
1.584 B
|
0.2%
|
93.0%
|
16.3
|
80.6%
|
